Literature DB >> 12361109

Adverse effects in 5 patients receiving EDTA at an outpatient chelation clinic.

Brent W Morgan1, Singleton Kori, Jerry D Thomas.   

Abstract

Despite limited scientific evidence, Na2EDTA chelation therapy has been advocated for a variety of conditions including atherosclerosis. Five patients presented with symptoms that developed 30 min-2 h into chelation therapy at an outpatient clinic with infusions of sterile waterwith 3 g Na2EDTA, 2 g MgCl, 100 mg B12, 100 mg B6, 1 ml bit B complex and 15 g Vit C; 1 patient also received 10 ml of 50% DMSO iv. All patients experienced gastrointestinal and musculoskeletal symptoms. Additional effects were (4/5), excessive thirst (4/5), and diaphoresis (4/5). On presentation patients were hypotensive (5/5), tachycardic (4/5) and febrile (5/5). Therapy included iv. fluids (5/5), dopamine (1/5), and ivantibiotics (4/5). Initial data showed leukopenia (5/5), thrombocytopenia (3/5), bandemia (4/5), EKG abnormalities of unknown acuity (5/5), and transient, mild rise in serum creatinine (3/4). All patients were discharged without permanent sequelae. It is unclear if effects were related to dose or rate of administration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12361109

Source DB:  PubMed          Journal:  Vet Hum Toxicol        ISSN: 0145-6296


  4 in total

1.  Fatalities after CAM: an overview.

Authors:  Edzard Ernst
Journal:  Br J Gen Pract       Date:  2011-06       Impact factor: 5.386

2.  Chelation for autism spectrum disorder (ASD).

Authors:  Stephen James; Shawn W Stevenson; Natalie Silove; Katrina Williams
Journal:  Cochrane Database Syst Rev       Date:  2015-05-11

3.  Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned.

Authors:  Kimball C Atwood; Elizabeth Woeckner; Robert S Baratz; Wallace I Sampson
Journal:  Medscape J Med       Date:  2008-05-13

Review 4.  EDTA chelation therapy for cardiovascular disease: a systematic review.

Authors:  Dugald M R Seely; Ping Wu; Edward J Mills
Journal:  BMC Cardiovasc Disord       Date:  2005-11-01       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.